Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 10:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 75 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo metered-dose inhaler Clear all
Completed Phase 4 Interventional Results available

Phase IV Study in Asthma Subjects for Dry Powder Inhaler (DPI) Versus (vs) Metered Dose Inhaler (MDI) Correct Use

NCT02794480
View directory record Official record
Conditions
Asthma
Interventions
ELLIPTA DPI, GSK MDI, AZ MDI
Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
20
States / cities
Huntington Beach, California • Aventura, Florida • Clearwater, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Sep 26, 2026, 10:37 AM EDT
Completed Phase 2 Interventional Results available

Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma

NCT02433834
View directory record Official record
Conditions
Asthma
Interventions
Glycopyrronium MDI, Serevent Diskus 50 μg, Placebo
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
43
States / cities
Birmingham, Alabama • Anaheim, California • Bakersfield, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 26, 2026, 10:37 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)

NCT01854645
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
GFF MDI, GP MDI, FF MDI, Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®), Placebo MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
2,103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
121
States / cities
Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 118 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Sep 26, 2026, 10:37 AM EDT
Terminated Phase 2 Interventional Results available

A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)

NCT03170232
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Danirixin 35 mg tablets, Placebo, Metered dose inhaler (MDI) sensor device, Rescue medication
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 76 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
11
States / cities
Birmingham, Alabama • San Diego, California • Torrance, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Sep 26, 2026, 10:37 AM EDT
Completed Phase 3 Interventional Results available

Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma

NCT02139644
View directory record Official record
Conditions
Asthma
Interventions
FS MDPI, Fp MDPI, Placebo MDPI, albuterol/salbutamol, Beclomethasone dipropionate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
76
States / cities
Birmingham, Alabama • Glendale, Arizona • Cypress, California + 64 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Sep 26, 2026, 10:37 AM EDT
Completed Not applicable Interventional

Effectiveness and Cost Study Comparing Two Ways to Deliver Albuterol for the Treatment of Asthma in the Hospital

NCT00623688
View directory record Official record
Conditions
Status Asthmaticus
Interventions
Metered Dose Inhaler & Optichamber Advantage Valve Holding Chamber (VHC), Airlife Sidestream High Efficiency Nebulizer
Device
Lead sponsor
Akron Children's Hospital
Other
Eligibility
12 Months to 18 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Sep 26, 2026, 10:37 AM EDT
Completed Phase 3 Interventional

Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid

NCT00174733
View directory record Official record
Conditions
Asthma
Interventions
Ciclesonide (XRP1526)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 7, 2009 · Synced Sep 26, 2026, 10:37 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD

NCT02343458
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
GFF MDI (PT003), FF MDI (PT005), GP MDI (PT001), Placebo MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
1,756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
44
States / cities
Andalusia, Alabama • Birmingham, Alabama • Foley, Alabama + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Sep 26, 2026, 10:37 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma

NCT03847896
View directory record Official record
Conditions
Asthma
Interventions
Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 160/180 μg (high dose), Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 80/180 μg (low dose), Budesonide metered dose inhaler / BD MDI 160 µg, Albuterol sulfate metered dose inhaler / AS MDI 180 μg, Placebo metered-dose inhaler / Placebo MDI
Combination Product · Drug · Other
Lead sponsor
Bond Avillion 2 Development LP
Industry
Eligibility
4 Years and older
Enrollment
1,001 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
73
States / cities
Mobile, Alabama • Bakersfield, California • Costa Mesa, California + 60 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Sep 26, 2026, 10:37 AM EDT
Withdrawn Phase 2 Interventional

Repeated High-dose Inhaled Corticosteroids for Asthma

NCT00695604
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Fluticasone
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Sep 26, 2026, 10:37 AM EDT
Terminated Phase 2 Interventional Results available

Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy

NCT01397162
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate, Placebo, BI 54903
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
41
States / cities
Fountain Valley, California • Huntington Beach, California • Long Beach, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Sep 26, 2026, 10:37 AM EDT
Completed Phase 3 Interventional

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma

NCT00393991
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate/formoterol fumarate 100/10, Fluticasone propionate 100, Formoterol fumarate 10, Placebo
Drug
Lead sponsor
SkyePharma AG
Industry
Eligibility
12 Years and older
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
47
States / cities
Pell City, Alabama • Scottsdale, Arizona • Cypress, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Sep 26, 2026, 10:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Safety of Repeated Doses of OP0201 Metered Dose Inhaler Compared to Placebo in Healthy Adult Volunteers

NCT03748758
View directory record Official record
Conditions
Healthy Adult Volunteers
Interventions
Drug: OP0201, Drug: Placebo
Combination Product
Lead sponsor
Novus Therapeutics, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Sep 26, 2026, 10:37 AM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma

NCT06644924
View directory record Official record
Conditions
Asthma
Interventions
Intervention: AS MDI, Intervention: Ventolin Evohaler, Intervention: Placebo matching AS MDI
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
22
States / cities
Encinitas, California • Lancaster, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 26, 2026, 10:37 AM EDT
Completed Phase 1 Interventional

FLOVENT Hydrofluoroalkane (HFA) In 6-12 Month Old Subjects

NCT00370097
View directory record Official record
Conditions
Asthma
Interventions
FLOVENT (fluticasone propionate) HFA, Placebo HFA
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 12 Months
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
Huntington Beach, California • Centennial, Colorado • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Sep 26, 2026, 10:37 AM EDT
Completed Phase 3 Interventional

Evaluation of Two Doses of QVAR by Breath Operated and Metered Dose Inhalers in Asthmatic Children

NCT00094016
View directory record Official record
Conditions
Asthma
Interventions
beclomethasone dipropionate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
5 Years to 11 Years
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
37
States / cities
Huntington Beach, California • Long Beach, California • Mission Viejo, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Sep 26, 2026, 10:37 AM EDT
Completed Phase 3 Interventional Results available

Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects

NCT00909779
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Arformoterol, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
40 Years and older
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
73
States / cities
Birmingham, Alabama • Brimingham, Alabama • Jasper, Alabama + 61 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2013 · Synced Sep 26, 2026, 10:37 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache

NCT00123201
View directory record Official record
Conditions
Migraine With Aura, Migraine Without Aura
Interventions
Dronabinol MDI
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
29
States / cities
Huntsville, Alabama • Tucson, Arizona • Anaheim, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Sep 26, 2026, 10:37 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients

NCT01899144
View directory record Official record
Conditions
Asthma
Interventions
Albuterol Spiromax, ProAir HFA, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
22
States / cities
Birmingham, Alabama • Little Rock, Alaska • Costa Mesa, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Sep 26, 2026, 10:37 AM EDT
Completed Phase 4 Interventional Results available

An Open-label Study to Evaluate Correct Use and Ease of Use of the ELLIPTA DPI in Pediatric Subjects With Asthma

NCT03478657
View directory record Official record
Conditions
Asthma
Interventions
Placebo DPI, ELLIPTA DPI, Ease of use questionnaires
Drug · Device · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 11 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
15
States / cities
Little Rock, Arkansas • Huntington Beach, California • Napa, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 26, 2026, 10:37 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers and COPD Patients to Evaluate the Efficacy and Safety of Inhaled TV46017

NCT02315131
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD
Interventions
TV46017, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
20 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
St Louis, Missouri • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 26, 2026, 10:37 AM EDT
Completed Phase 3 Interventional Results available

Albuterol HFA MDI in Pediatric Participants With Asthma

NCT00577655
View directory record Official record
Conditions
Asthma
Interventions
Albuterol, Placebo, Proventil® HFA
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
13
States / cities
Huntington Beach, California • Palmdale, California • Paramount, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Sep 26, 2026, 10:37 AM EDT
Terminated Phase 3 Interventional Results available

A Twelve Month Long Term Safety Study to Evaluate the Safety of Albuterol in a Dry Powder Inhaler With Both Repeated and as Needed Dosing

NCT01218009
View directory record Official record
Conditions
Asthma
Interventions
Placebo Spiromax, Albuterol Spiromax
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
30
States / cities
Scottsdale, Arizona • Los Angeles, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Sep 26, 2026, 10:37 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Evaluation of Efficacy and Safety for Single Dose of E004 in Children With Asthma

NCT01737905
View directory record Official record
Conditions
Asthma
Interventions
Epinephrine HFA-MDI (E004), Placebo-HFA
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
6
States / cities
Cypress, California • Medford, Oregon • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Sep 26, 2026, 10:37 AM EDT